Baby Safety / Compounds / Xylazine

Is Xylazine safe for babies and kids?

High risk for kids

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Xylazine poses heightened risk.

What is xylazine?

The IUPAC name is N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine.

Also known as: N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine, Xilazina, Chanazine, Xylazinum.

IUPAC name
N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine
CAS number
7361-61-7
Molecular formula
C12H16N2S
Molecular weight
220.34 g/mol
SMILES
CC1=C(C(=CC=C1)C)NC2=NCCCS2
PubChem CID
5707

Risk for babies

High risk

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Xylazine poses heightened risk.

Neonates and infants up to 12 months have incomplete blood-brain barrier development, immature Phase I/II metabolic enzymes (particularly CYP3A4, UGT1A1), and higher gastrointestinal permeability. Equivalent doses produce higher internal concentrations and longer residence times.

What to do: Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

Risk for pregnant and nursing people

Elevated risk

Xylazine poses pregnancy risk through potential teratogenicity, altered pharmacokinetics (increased blood volume, changed CYP activity), and placental transfer. FDA pregnancy category should be evaluated.

Suspected reproductive toxicant (GHS H361) or suspected endocrine disruptor. Precautionary approach warranted. Animal studies or limited human data suggest developmental toxicity potential.

What to do: Minimize exposure during pregnancy and lactation. Consult healthcare provider regarding specific risks. Consider alternative products with lower hazard profiles.

Regulatory consensus

2 regulatory and scientific bodies have classified Xylazine. The classifications differ — that's the data.

AgencyYearClassificationNotes
EPA CTX / Skin-Eye—Eye Irritation: Category 6.4A (Category 2A) (score: high)
EPA CTX / Skin-Eye—Skin Irritation: Category 6.3A (Category 2) (score: high)

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where kids encounter xylazine

  • Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
  • Occupational Environments — Factories, Warehouses, Transportation vehicles

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Xylazine:

  • Therapeutic alternatives (consult prescriber)
    Trade-offs: Drug-specific. Cannot substitute without medical guidance.
    Relative cost: 1.2-2×

Frequently asked questions

Is xylazine safe for kids?

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Xylazine poses heightened risk.

What products contain xylazine?

Xylazine appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).

What should I do if my child is exposed to xylazine?

Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

See Xylazine in the baby app

Look up products containing xylazine, compare to alternatives, and explore the full data record.

Open in baby View raw API data

Sources (3)
  1. US FDA: Xylazine — Veterinary Sedative Use, Alpha-2 Agonist Mechanism, Species Dose Differences, Cardiovascular Monitoring Requirements, Atipamezole Reversal, and 2023 Safety Alert Regarding Illicit Drug Supply Adulteration (2023) (2023) — regulatory
  2. US CDC: Xylazine in the Illicit Drug Supply — Prevalence in Fentanyl Mixtures (Tranq), Naloxone Non-Reversal of Alpha-2 Agonist Effects, Necrotic Wound Syndrome, Overdose Management, and National Spread from Philadelphia (2023) (2023) — regulatory
  3. ASPCA Animal Poison Control Center: Xylazine in Dogs and Cats — Emetic Response in Cats, Cardiovascular Effects, Dose Comparison, and Atipamezole Reversal (2021) (2021) — veterinary

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →